NCT06388369 - Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2028

Conditions

Very High Risk Prostate Carcinoma

Interventions

RADIATION

[177Lu]Lu-PSMA-617

2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals

DRUG

Ipilimumab

4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals

Trial Locations (1)

University Hospital Essen, Clinic of Urology, Essen